The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
暂无分享,去创建一个
R. Lockey | R. Pawankar | W. Aberer | M. Gompels | W. Lumry | H. Farkas | P. Busse | B. Ritchie | T. Craig | M. Sanchez‐Borges | I. Ansotegui | L. Rosenwasser | K. Bork | E. Aygören‐Pürsün | A. Nast | C. Katelaris | A. Kaplan | M. Maurer | H. Longhurst | M. Magerl | M. Hide | Farrukh R. Sheikh | M. Riedl | A. Banerji | P. Potter | G. Porebski | P. Spaeth | I. Martínez-Saguer | L. Bouillet | B. Zuraw | S. Kiani-Alikhan | N. Prior | W. Lei | William B. Smith | D. Csuka | A. Reshef | A. Zanichelli | A. Grumach | L. Varga | K. Weller | Y. Zhi | A. Bygum | H. Kang | T. Caballero | T. Bowen | M. Stobiecki | D. Cohn | R. Gower | H. Boysen | S. Betschel | D. Moldovan | J. Peter | J. M. Matta Campos | A. Castaldo | A. Malbrán | A. MacGinnitie | G. Guidos-Fogelbach | N. Brodszki | I. Martinez Saguer | M. Cancian | N. Bara | I. Boccon-Gibod | Dinh Nguyen | S. Nieto‐Martinez | E. Toubi | D. Nguyen | Wei-Te Lei | Wei‐Te Lei | G. Porębski
[1] M. Levi,et al. COVID-19 vaccination and the risk of swellings in patients with hereditary angioedema , 2021, The Journal of Allergy and Clinical Immunology: In Practice.
[2] G. Karakaya,et al. Effect of COVID-19 on hereditary angioedema activity and quality of life. , 2021, Allergy and asthma proceedings.
[3] J. Bernstein,et al. Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study , 2021, Allergy.
[4] A. Nicolas,et al. [Impact of disease on daily activities, emotions and quality of life of patients with hereditary angioedema]. , 2021, La Revue de medecine interne.
[5] M. Maurer,et al. Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema☆ , 2021, The World Allergy Organization journal.
[6] M. Manning,et al. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies. , 2021, Allergy and asthma proceedings.
[7] H. Iocca,et al. Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study , 2021, Clinical and translational allergy.
[8] S. Waserman,et al. How to Measure Disease Activity, Impact, and Control in Patients with Recurrent Wheals, Angioedema, or Both. , 2021, The journal of allergy and clinical immunology. In practice.
[9] J. Bernstein,et al. Consensus on treatment goals in hereditary angioedema: a global Delphi initiative. , 2021, The Journal of allergy and clinical immunology.
[10] R. Krüger,et al. Lanadelumab efficacy, safety, and injection interval extension in HAE - a real life study. , 2021, The journal of allergy and clinical immunology. In practice.
[11] W. Aberer,et al. Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema , 2021, Clinical Reviews in Allergy & Immunology.
[12] C. Maas,et al. Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema , 2021, Clinical Reviews in Allergy & Immunology.
[13] D. Mungan,et al. Psychiatric and Clinical Characteristics of Hereditary Angioedema Patients Who Experienced Attacks during COVID-19. , 2021, Journal of investigational allergology & clinical immunology.
[14] M. Mesquita,et al. Acute urticaria in children: from pediatric emergency department to allergology consultation at a central hospital. , 2021, European annals of allergy and clinical immunology.
[15] T. Craig,et al. Short-term prophylaxis for children and adolescents with hereditary angioedema. , 2021, Allergy and asthma proceedings.
[16] J. Simon,et al. Prophylactic Treatment in Hereditary Angioedema Is Associated with Reduced Anxiety in Patients in Leipzig, Germany , 2021, International Archives of Allergy and Immunology.
[17] K. Weller,et al. Patient-reported Outcome Measures for Angioedema: A Literature Review , 2021, Acta dermato-venereologica.
[18] T. Craig,et al. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report , 2021, Allergy, Asthma & Clinical Immunology.
[19] J. Bernstein,et al. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2). , 2021, The journal of allergy and clinical immunology. In practice.
[20] M. Cicardi,et al. Hereditary angioedema due to C1 inhibitor deficiency in Belarus: epidemiology, access to diagnosis and seven novel mutations in SERPING1 gene , 2021, Clinical and Molecular Allergy.
[21] L. Arruda,et al. Hereditary angioedema: how to approach it at the emergency department? , 2021, Einstein.
[22] J. Bernstein,et al. Recognition, Evaluation, and Management of Pediatric Hereditary Angioedema. , 2021, Pediatric emergency care.
[23] D. Launay,et al. COVID‐19 as a trigger of acute attacks in people with hereditary angioedema , 2021, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[24] J. Pesquero,et al. Unnecessary Abdominal Surgeries in Attacks of Hereditary Angioedema with Normal C1 Inhibitor , 2021, Clinical Reviews in Allergy & Immunology.
[25] H. Farkas,et al. How Angioedema Quality of Life Questionnaire Can Help Physicians in Treating C1-Inhibitor Deficiency Patients? , 2021, Clinical Reviews in Allergy & Immunology.
[26] E. Aygören‐Pürsün,et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey , 2021, Orphanet Journal of Rare Diseases.
[27] P. Keith,et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study , 2021, Orphanet Journal of Rare Diseases.
[28] B. Zuraw,et al. Assessing the cost and quality-of-life impact of on-demand- only medications for adults with hereditary angioedema. , 2021, Allergy and asthma proceedings.
[29] E. Aygören‐Pürsün,et al. Subcutaneous C1‐Inhibitor Concentrate for prophylaxis during pregnancy and lactation in a patient with C1‐INH‐HAE , 2021, Clinical case reports.
[30] R. Somech,et al. New Instrument for the Evaluation of Prodromes and Attacks of Hereditary Angioedema (HAE-EPA) , 2021, Clinical Reviews in Allergy & Immunology.
[31] M. Maurer,et al. Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell–Mediated Angioedema , 2021, Clinical Reviews in Allergy & Immunology.
[32] A. Reshef,et al. The Enigma of Prodromes in Hereditary Angioedema (HAE) , 2021, Clinical Reviews in Allergy & Immunology.
[33] A. Banerji,et al. Optimal Management of Hereditary Angioedema: Shared Decision-Making , 2021, Journal of asthma and allergy.
[34] F. Minafra,et al. The Challenges in the Follow-Up and Treatment of Brazilian Children with Hereditary Angioedema , 2021, International Archives of Allergy and Immunology.
[35] Britta S. Möhl,et al. Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation. , 2021, The Journal of allergy and clinical immunology.
[36] Darjan Kardum,et al. Successful treatment with Cinryze® replacement therapy of a pregnant patient with hereditary angioedema: a case report , 2021, Journal of Medical Case Reports.
[37] P. Kralickova,et al. Acquired Angioedema with C1 Inhibitor Deficiency: Occurrence, Clinical Features, and Management: A Nationwide Retrospective Study in the Czech Republic Patients , 2021, International Archives of Allergy and Immunology.
[38] J. Bernstein,et al. A robust multiplexed assay to quantify C1-inhibitor, C1q, and C4 proteins for in vitro diagnosis of hereditary angioedema from dried blood spot. , 2020, Journal of pharmaceutical and biomedical analysis.
[39] J. Bernstein,et al. Androgen use in hereditary angioedema: A critical appraisal and approaches to transitioning from androgens to other therapies. , 2020, Allergy and asthma proceedings.
[40] A. Emelyanov,et al. [Diagnosis and treatment of hereditary angioedema with normal C1-inhibitor level]. , 2020, Terapevticheskii arkhiv.
[41] S. Patro,et al. Acute Presentation of Undiagnosed Hereditary Angioedema of the Larynx: Averting Death. , 2020, Turkish archives of otorhinolaryngology.
[42] W. Lumry,et al. Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study , 2020, Allergy.
[43] E. Goudouris,et al. COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency , 2020, The Journal of Allergy and Clinical Immunology: In Practice.
[44] Yusuke Suzuki,et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial , 2020, Allergy.
[45] H. Farkas,et al. A follow‐up survey of patients with acquired angioedema due to C1‐inhibitor deficiency , 2020, Journal of internal medicine.
[46] J. Pines,et al. Recognition and Differential Diagnosis of Hereditary Angioedema in the Emergency Department. , 2020, The Journal of emergency medicine.
[47] T. Craig. Triggers and short-term prophylaxis in patients with hereditary angioedema. , 2020, Allergy and asthma proceedings.
[48] N. Maina,et al. Hereditary angioedema: Comprehensive management plans and patient support. , 2020, Allergy and asthma proceedings.
[49] W. Lumry,et al. Hereditary angioedema: Epidemiology and burden of disease. , 2020, Allergy and asthma proceedings.
[50] D. Johnston,et al. Hereditary angioedema: Special considerations in children. , 2020, Allergy and asthma proceedings.
[51] J. Bernstein,et al. Definition and classification of hereditary angioedema. , 2020, Allergy and asthma proceedings.
[52] H. Farkas,et al. Deciphering the Genetics of Primary Angioedema with Normal Levels of C1 Inhibitor , 2020, Journal of clinical medicine.
[53] William H. Yang,et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. , 2020, The Journal of allergy and clinical immunology.
[54] T. Machnig,et al. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence , 2020, Orphanet Journal of Rare Diseases.
[55] M. Wigand,et al. Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience. , 2020, Journal of drugs in dermatology : JDD.
[56] H. Farkas,et al. The importance of complement testing in acquired angioedema related to angiotensin-converting enzyme inhibitors. , 2020, The journal of allergy and clinical immunology. In practice.
[57] J. Bernstein,et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. , 2020, The journal of allergy and clinical immunology. In practice.
[58] M. Kowalski,et al. Angioedema. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society (PTD) and Polish Society of Allergology (PTA) , 2020, Postepy dermatologii i alergologii.
[59] S. Fayyaz,et al. Novel Use of Fresh Frozen Plasma in Treating Hereditary Angioedema: A Success Story From Pakistan , 2020, Cureus.
[60] P. Jeandel,et al. [Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment]. , 2020, La Revue de medecine interne.
[61] M. Margaglione,et al. A myoferlin gain‐of‐function variant associates with a new type of hereditary angioedema , 2020, Allergy.
[62] R. Krüger,et al. Hereditary angioedema in children and adolescents – A consensus update on therapeutic strategies for German‐speaking countries , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[63] Kevin J. Burnham,et al. Thromboembolic Risk of C1 Esterase Inhibitors: A Systematic Review on Current Evidence , 2020, Expert review of clinical pharmacology.
[64] J. Bernstein,et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks , 2020, Allergy.
[65] Praveen Sankrithi,et al. Pregnancy-Induced Exacerbation of Hereditary Angioedema in a Multiparous Caucasian Female , 2020, Cureus.
[66] J. Poza Cordón,et al. Ultrasound findings in an abdominal crisis of a patient with hereditary angioedema. , 2020, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[67] Todor A Popov,et al. Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence , 2020, Allergy.
[68] M. Riedl,et al. Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review. , 2020, The journal of allergy and clinical immunology. In practice.
[69] C. Katelaris. Self-Management Plans in Patients with Hereditary Angioedema: Strategies, Outcomes and Integration into Clinical Care , 2020, Journal of asthma and allergy.
[70] G. Porebski,et al. Life-threatening laryngeal attacks in hereditary angioedema patients. , 2020, Otolaryngologia polska = The Polish otolaryngology.
[71] T. Zuberbier,et al. Validation of the Angioedema Control Test (AECT) - a patient reported outcome instrument for assessing angioedema control. , 2020, The journal of allergy and clinical immunology. In practice.
[72] T. Brown,et al. Patient-reported burden of hereditary angioedema: findings from a US patient survey. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[73] T. Machnig,et al. Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene , 2020, Orphanet Journal of Rare Diseases.
[74] L. Bouillet,et al. Update on bradykinin-mediated angioedema in 2020. , 2020, Therapie.
[75] B. Zuraw,et al. Contact System Activation During Erythema Marginatum In Hereditary Angioedema. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[76] N. Prior,et al. HAE-AS, a specific disease activity scale for hereditary angioedema with C1-inhibitor deficiency. , 2020, Journal of investigational allergology & clinical immunology.
[77] Moshe Y. Vardi,et al. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY]. , 2020, Arerugi = [Allergy].
[78] T. Hoffmann,et al. Successful Long-Term Prophylactic Treatment With Subcutaneous C1 Esterase Inhibitor in a Patient With Hereditary Angioedema , 2020, Journal of pharmacy practice.
[79] S. Cichon,et al. International consensus on the use of genetics in the management of hereditary angioedema. , 2020, The journal of allergy and clinical immunology. In practice.
[80] R. Shapiro,et al. Recombinant Human C1 Esterase Inhibitor as Short-Term Prophylaxis in Patients With Hereditary Angioedema. , 2020, The journal of allergy and clinical immunology. In practice.
[81] M. López-Trascasa,et al. SERPING1 mutation update: Mutation spectrum and C1 Inhibitor phenotypes , 2019, Human mutation.
[82] M. Margaglione,et al. Impaired control of the contact system in hereditary angioedema with normal C1‐inhibitor , 2019, Allergy.
[83] T. Zuberbier,et al. Development of the Angioedema Control Test—A patient‐reported outcome measure that assesses disease control in patients with recurrent angioedema , 2019, Allergy.
[84] T. Simon,et al. Manufacturing of plasma-derived C1-inhibitor concentrate for treatment of patients with hereditary angioedema. , 2019, Allergy and asthma proceedings.
[85] T. Zuberbier,et al. Diagnosis and treatment of chronic inducible urticaria , 2019, Allergy.
[86] P. Keith,et al. The International/Canadian Hereditary Angioedema Guideline , 2019, Allergy, Asthma & Clinical Immunology.
[87] J. Bernstein,et al. Safety of Recombinant Human C1 Esterase Inhibitor for Hereditary Angioedema Attacks During Pregnancy. , 2019, The journal of allergy and clinical immunology. In practice.
[88] M. Maurer,et al. Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients , 2019, BioMed research international.
[89] M. Maurer,et al. Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change , 2019, Health and Quality of Life Outcomes.
[90] L. Brussino,et al. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research , 2019, Drugs in context.
[91] M. Levin,et al. Fresh frozen plasma for on-demand hereditary angioedema treatment in South Africa and Iran , 2019, The World Allergy Organization journal.
[92] T. Machnig,et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study , 2019, Allergy, Asthma & Clinical Immunology.
[93] C. Maas,et al. Hereditary Angioedema: Insights into inflammation and allergy. , 2019, Molecular immunology.
[94] B. Long,et al. Evaluation and Management of Angioedema in the Emergency Department , 2019, The western journal of emergency medicine.
[95] S. Valle,et al. Hereditary angioedema: Screening of first-degree blood relatives and earlier diagnosis. , 2019, Allergy and asthma proceedings.
[96] William H. Yang,et al. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. , 2019, The journal of allergy and clinical immunology. In practice.
[97] I. Braenne,et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N‐terminal cleavage site of bradykinin , 2019, Allergy.
[98] H. Farkas,et al. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children , 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[99] William H. Yang,et al. Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study. , 2019, The journal of allergy and clinical immunology. In practice.
[100] Moshe Y. Vardi,et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema , 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[101] Ş. Pırıldar,et al. The impact of hereditary angioedema on quality of life and family planning decisions , 2019, International journal of psychiatry in medicine.
[102] K. Bork,et al. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate , 2019, Orphanet Journal of Rare Diseases.
[103] T. Machnig,et al. Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks , 2019, Allergy, Asthma & Clinical Immunology.
[104] G. Hayman,et al. Chronic spontaneous urticaria and angioedema requiring treatment with omalizumab in a patient with hereditary angioedema. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[105] T. Horiuchi,et al. A novel C1 inhibitor gene mutation in a family with hereditary angioedema: Use of genetic analysis to facilitate early diagnosis. , 2019, Allergology international : official journal of the Japanese Society of Allergology.
[106] W. Lumry,et al. Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[107] M. Maurer,et al. Klassifikation und Pathophysiologie von Angioödemen , 2018, Der Hautarzt.
[108] William H. Yang,et al. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial , 2018, JAMA.
[109] Gabriella Gábos,et al. Consequences of Misdiagnosed and Mismanaged Hereditary Angioedema Laryngeal Attacks: An Overview of Cases from the Romanian Registry , 2018, Case reports in emergency medicine.
[110] M. Cicardi,et al. Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema , 2018, Expert review of clinical immunology.
[111] P. Keith,et al. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. , 2018, The journal of allergy and clinical immunology. In practice.
[112] M. Triggiani,et al. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema , 2018, The New England journal of medicine.
[113] C. Maas,et al. Hereditary angioedema: the plasma contact system out of control , 2018, Journal of thrombosis and haemostasis : JTH.
[114] M. Cicardi,et al. Angioedema Due to Bradykinin Dysregulation. , 2018, The journal of allergy and clinical immunology. In practice.
[115] T. Zuberbier,et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria , 2018, Allergy.
[116] M. Triggiani,et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study , 2018, Allergy.
[117] M. Riedl,et al. Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema , 2018, Clinical Reviews in Allergy & Immunology.
[118] P. Schmid‐Grendelmeier,et al. Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema , 2018, Orphanet Journal of Rare Diseases.
[119] H. Farkas,et al. Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years , 2018, Expert review of clinical immunology.
[120] A. Maetzel,et al. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies , 2018, Orphanet Journal of Rare Diseases.
[121] A. Zanichelli,et al. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study , 2018, Orphanet Journal of Rare Diseases.
[122] R. Lockey,et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update , 2018, Allergy.
[123] H. Longhurst. Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus , 2018, Front. Med..
[124] I. Braenne,et al. Hereditary angioedema with a mutation in the plasminogen gene , 2018, Allergy.
[125] T. Nakayama,et al. Comparison of the Frequency of Angioedema Attack, before and during Pregnancy, in a Patient with Type I Hereditary Angioedema , 2017, Internal medicine.
[126] M. Margaglione,et al. Mutation of the angiopoietin‐1 gene (ANGPT1) associates with a new type of hereditary angioedema , 2017, The Journal of allergy and clinical immunology.
[127] T. Hoffmann,et al. [The ulm emergency algorithm for the acute treatment of drug-induced, bradykinin-mediated angioedema]. , 2018, Medizinische Klinik, Intensivmedizin und Notfallmedizin.
[128] G. Mortier,et al. Hereditary angioedema in 2 sisters due to paternal gonadal mosaicism. , 2018, The journal of allergy and clinical immunology. In practice.
[129] P. Busse,et al. Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema , 2017, Front. Med..
[130] Jimmy Gonzalez,et al. Angiotensin‐converting enzyme inhibitor–induced angioedema: A review of the literature , 2017, Journal of clinical hypertension.
[131] C. Wahlgren,et al. Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden. , 2017, Allergy and asthma proceedings.
[132] W. Aberer,et al. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. , 2017, The journal of allergy and clinical immunology. In practice.
[133] T. Kelbel,et al. Multiple doses of icatibant used during pregnancy , 2017, Allergy & rhinology.
[134] C. Koch,et al. Complement factor C4 activation in patients with hereditary angioedema. , 2017, Clinical biochemistry.
[135] M. Cicardi,et al. Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency. , 2017, The journal of allergy and clinical immunology. In practice.
[136] S. Betschel,et al. The Clinical Evaluation of Angioedema. , 2017, Immunology and allergy clinics of North America.
[137] N. Prior,et al. Burden of Illness and Quality-of-Life Measures in Angioedema Conditions. , 2017, Immunology and allergy clinics of North America.
[138] C. Maas,et al. Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment. , 2017, Immunology and allergy clinics of North America.
[139] W. Aberer,et al. Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey , 2017, Allergy, Asthma & Clinical Immunology.
[140] J. Edelman,et al. Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema. , 2017, Allergy and asthma proceedings.
[141] William H. Yang,et al. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor , 2017, The New England journal of medicine.
[142] D. Supina,et al. Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. , 2017, Allergy and asthma proceedings.
[143] C. Fagerberg,et al. Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema , 2017, Orphanet Journal of Rare Diseases.
[144] T. Machnig,et al. Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema , 2017, Allergy & rhinology.
[145] B. Floccard,et al. Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a French cohort , 2017, European Journal of Dermatology.
[146] A. Forrest,et al. Hereditary angioedema: death after a dental extraction. , 2017, Australian dental journal.
[147] R. Lockey,et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis , 2017 .
[148] C. von Buchwald,et al. Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema , 2017, International journal of otolaryngology.
[149] K. Bork,et al. Treatment for hereditary angioedema with normal C1‐INH and specific mutations in the F12 gene (HAE‐FXII) , 2017, Allergy.
[150] M. Triggiani,et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency , 2016, Allergy.
[151] J. Bernstein,et al. Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[152] H. Farkas,et al. Bacteriuria increases the risk of edematous attacks in hereditary angioedema with C1‐inhibitor deficiency , 2016, Allergy.
[153] T. Renné,et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. , 2016, The Journal of allergy and clinical immunology.
[154] J. Bernstein,et al. Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency , 2016, Pediatrics.
[155] M. Triggiani,et al. High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study , 2016, Orphanet Journal of Rare Diseases.
[156] Huamin H. Li. Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance , 2016, Patient preference and adherence.
[157] J. Bernstein,et al. Expert perspectives on hereditary angioedema: Key areas for advancements in care across the patient journey , 2016, Allergy & rhinology.
[158] B. Zuraw,et al. Tolerability and Effectiveness of 17-α-Alkylated Androgen Therapy for Hereditary Angioedema: A Re-examination. , 2016, The journal of allergy and clinical immunology. In practice.
[159] W. Kreuz,et al. Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat. , 2016, The Journal of allergy and clinical immunology.
[160] J. Bernstein,et al. Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data. , 2016, The journal of allergy and clinical immunology. In practice.
[161] B. Zuraw,et al. Pediatric Hereditary Angioedema , 2016, Clinical pediatrics.
[162] V. Leblond,et al. A nationwide study of acquired C1-inhibitor deficiency in France , 2016, Medicine.
[163] M. Maurer,et al. Effect of omalizumab on angioedema in H1‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ACT, a randomized controlled trial , 2016, Allergy.
[164] P. Martus,et al. The Angioedema Quality of Life Questionnaire (AE‐QoL) – assessment of sensitivity to change and minimal clinically important difference , 2016, Allergy. European Journal of Allergy and Clinical Immunology.
[165] H. Farkas,et al. First report of icatibant treatment in a pregnant patient with hereditary angioedema , 2016, The journal of obstetrics and gynaecology research.
[166] B. Zuraw,et al. HAE Pathophysiology and Underlying Mechanisms , 2016, Clinical Reviews in Allergy & Immunology.
[167] M. Kidon,et al. The Story of Angioedema: from Quincke to Bradykinin , 2016, Clinical Reviews in Allergy & Immunology.
[168] A. Kaplan,et al. Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent , 2016, Clinical Reviews in Allergy & Immunology.
[169] M. Magerl,et al. An analysis of the teaching of intravenous self‐administration in patients with hereditary angio‐oedema , 2016, Clinical and experimental dermatology.
[170] H. Farkas. Icatibant as acute treatment for hereditary angioedema in adults , 2016, Expert review of clinical pharmacology.
[171] H. Farkas,et al. “Nuts and Bolts” of Laboratory Evaluation of Angioedema , 2016, Clinical Reviews in Allergy & Immunology.
[172] T. Renné,et al. Urticaria as a Presenting Prodromal Manifestation of Attacks of Hereditary Angioedema. , 2016, Acta dermato-venereologica.
[173] W. Aberer,et al. Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL. , 2016, The journal of allergy and clinical immunology. In practice.
[174] L. Aagaard,et al. Real-life experience with long-term prophylactic C1 inhibitor concentrate treatment of patients with hereditary angioedema: Effectiveness and cost. , 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[175] M. Speletas,et al. Genetics of Hereditary Angioedema Revisited , 2016, Clinical Reviews in Allergy & Immunology.
[176] T. Machnig,et al. Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency. , 2016, The Journal of emergency medicine.
[177] M. Magerl,et al. Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[178] H. Farkas,et al. Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor. , 2016, Allergy and asthma proceedings.
[179] R. Krüger,et al. Daily subcutaneous administration of human C1 inhibitor in a child with hereditary angioedema type 1 , 2016, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[180] J. Greve,et al. Prophylaxe beim hereditären Angioödem (HAE) mit C1‐Inhibitormangel , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[181] A. Bygum,et al. Urticaria and Prodromal Symptoms Including Erythema Marginatum in Danish Patients with Hereditary Angioedema. , 2016, Acta dermato-venereologica.
[182] H. Farkas,et al. The effect of long-term danazol treatment on haematological parameters in hereditary angioedema , 2016, Orphanet Journal of Rare Diseases.
[183] H. Farkas,et al. Erythema Marginatum as an Early Symptom of Hereditary Angioedema: Case Report of 2 Newborns , 2016, Pediatrics.
[184] H. Longhurst,et al. Optimizing hereditary angioedema management through tailored treatment approaches , 2016, Expert review of clinical immunology.
[185] R. Krüger,et al. Subcutaneous self‐injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angio‐oedema , 2016, Clinical and experimental dermatology.
[186] W. Aberer,et al. Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema. , 2016, Journal of investigational allergology & clinical immunology.
[187] C. Marcos,et al. Management of Pregnancy and Delivery in Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency. , 2016, Journal of investigational allergology & clinical immunology.
[188] G. Casazza,et al. Efficacy of on‐demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency , 2015, Allergy.
[189] W. Lumry,et al. Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[190] P. Staubach,et al. High-Concentration Liquid Prednisolone Formula: Filling a Therapeutic Niche in Severe Acute Attacks of Urticaria and Angioedema , 2015, Skin Pharmacology and Physiology.
[191] G. Kojda,et al. Angioedema induced by cardiovascular drugs: new players join old friends , 2015, Allergy.
[192] W. Aberer,et al. Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey. , 2015, Allergy and asthma proceedings.
[193] J. Bernstein,et al. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate , 2015, Allergy.
[194] J. Bernstein,et al. Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. , 2015, Immunotherapy.
[195] W. Aberer,et al. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals , 2015, International Archives of Allergy and Immunology.
[196] M. Riedl. Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema , 2015, Clinical Drug Investigation.
[197] M. Boubaya,et al. Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[198] M. Gompels,et al. C1 inhibitor deficiency: 2014 United Kingdom consensus document , 2015, Clinical and experimental immunology.
[199] Y. Benhamou,et al. Icatibant in ACE-inhibitor-induced angioedema. , 2015, The New England journal of medicine.
[200] S. Neri,et al. Use of subcutaneous‐C1 INH for acute therapy and prophylaxis of a child with HAE , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[201] A. Gompel,et al. [Hereditary angiœdema treatments: Recommendations from the French national center for angiœdema (Bordeaux consensus 2014)]. , 2015, Presse medicale.
[202] J. Bernstein,et al. Current state of hereditary angioedema management: a patient survey. , 2015, Allergy and asthma proceedings.
[203] Y. Makino,et al. [Perioperative Management of a Patient with Hereditary Angioedema: A Case Report]. , 2015, Masui. The Japanese journal of anesthesiology.
[204] M. Riedl. Critical appraisal of androgen use in hereditary angioedema: a systematic review. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[205] D. Launay,et al. Traitements des angiœdèmes héréditaires : recommandations du centre de référence national des angiœdèmes (consensus 2014 de Bordeaux) , 2015 .
[206] J. Biedenkapp,et al. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. , 2015, The journal of allergy and clinical immunology. In practice.
[207] J. Bernstein,et al. Facilitating home-based treatment of hereditary angioedema. , 2015, Allergy and asthma proceedings.
[208] J. Bernstein,et al. Before and after, the impact of available on-demand treatment for HAE. , 2015, Allergy and asthma proceedings.
[209] T. Craig,et al. Perioperative management for patients with hereditary angioedema , 2015, Allergy & rhinology.
[210] M. Triggiani,et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy , 2015, Orphanet Journal of Rare Diseases.
[211] A. Knulst,et al. Clinical similarities among bradykinin-mediated and mast cell-mediated subtypes of non-hereditary angioedema: a retrospective study , 2015, Clinical and Translational Allergy.
[212] A. Tordai,et al. Hereditary angioedema: molecular and clinical differences among European populations. , 2015, The Journal of allergy and clinical immunology.
[213] G. Kojda,et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. , 2015, The New England journal of medicine.
[214] M. López-Trascasa,et al. Complement Study Versus CINH Gene Testing for the Diagnosis of Type I Hereditary Angioedema in Children , 2015, Journal of Clinical Immunology.
[215] I. Boccon-Gibod. Angioedèmes héréditaires : traitements et éducation thérapeutique , 2015 .
[216] A. Zanichelli,et al. Icatibant Exposure During Pregnancy in a Patient With Hereditary Angioedema. , 2015, Journal of investigational allergology & clinical immunology.
[217] I. Boccon-Gibod. [Hereditary angioedema: treatment and educational therapeutic program]. , 2015, Presse medicale.
[218] J. Raoul,et al. Hepatocellular Carcinoma in a Noncirrhotic Liver after Long-Term Use of Danazol for Hereditary Angioedema , 2014, Case Reports in Oncology.
[219] H. Farkas,et al. Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema , 2014, Orphanet Journal of Rare Diseases.
[220] K. Bauer,et al. The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. , 2014, Allergy and asthma proceedings.
[221] P. Keith,et al. Canadian hereditary angioedema guideline , 2014, Allergy, Asthma & Clinical Immunology.
[222] GiladOded,et al. Outcome following tranexamic acid exposure during breastfeeding. , 2014 .
[223] J. Biedenkapp,et al. A phase 1 study investigating DX-2930 in healthy subjects. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[224] A. Bygum,et al. Hereditary Angioedema: Children Should be Considered for Training in Self‐Administration , 2014, Pediatric dermatology.
[225] R. Cabañas,et al. Management of hereditary angioedema in pregnant women: a review , 2014 .
[226] W. Lumry,et al. Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. , 2014, Allergy and asthma proceedings.
[227] J. Bernstein,et al. A cross-sectional questionnaire assessing patient and physician use of short-term prophylaxis for hereditary angioedema. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[228] A. Bygum. Hereditary angioedema - consequences of a new treatment paradigm in Denmark. , 2014, Acta dermato-venereologica.
[229] T. Zuberbier,et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.
[230] T. Craig,et al. Barriers to self-administered therapy for hereditary angioedema. , 2014, Allergy and asthma proceedings.
[231] M. Triggiani,et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group , 2014, Allergy.
[232] J. Sheikh,et al. The diagnosis and management of acute and chronic urticaria: 2014 update. , 2014, The Journal of allergy and clinical immunology.
[233] W. Kreuz,et al. Characterization of prodromal symptoms in a large population of patients with hereditary angio‐oedema , 2014, Clinical and experimental dermatology.
[234] B. Feldman,et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. , 2014, Journal of clinical epidemiology.
[235] M. Kirschfink,et al. Complement Profile in Neonates of Different Gestational Ages , 2014, Scandinavian journal of immunology.
[236] H. Farkas,et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency , 2014, Orphanet Journal of Rare Diseases.
[237] W. Aberer,et al. Open‐label, multicenter study of self‐administered icatibant for attacks of hereditary angioedema , 2014, Allergy.
[238] J. Bernstein,et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[239] S. Fernando,et al. Hereditary cause of severe recurrent bowel swelling that requires targeted therapy , 2014, The Medical journal of Australia.
[240] T. Rossmanith,et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study , 2013, Transfusion.
[241] B. Stahl,et al. Outcome following tranexamic acid exposure during breastfeeding. , 2014, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.
[242] J. Bernstein,et al. Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. , 2014, The journal of allergy and clinical immunology. In practice.
[243] C. Verhoef,et al. Hepatocellular carcinoma after danazol treatment for hereditary angio-oedema. , 2014, The Netherlands journal of medicine.
[244] T. Renné,et al. Bradykinin in health and disease: proceedings of the Bradykinin Symposium 2012, Berlin 23–24 August 2012 , 2014, Inflammation Research.
[245] C. Hack,et al. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. , 2013, British journal of clinical pharmacology.
[246] M. Frank. Update on preventive therapy (prophylaxis) for hereditary angioedema. , 2013, Immunology and allergy clinics of North America.
[247] T. Craig,et al. Assessment of hereditary angioedema treatment risks. , 2013, Allergy and asthma proceedings.
[248] A. Gompel,et al. Hereditary angioedema in women: specific challenges. , 2013, Immunology and allergy clinics of North America.
[249] M. Riedl. Creating a comprehensive treatment plan for hereditary angioedema. , 2013, Immunology and allergy clinics of North America.
[250] P. Martus,et al. Development, validation, and initial results of the Angioedema Activity Score , 2013, Allergy.
[251] T. Machnig,et al. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[252] J. Bernstein,et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. , 2013, The journal of allergy and clinical immunology. In practice.
[253] T. Klingebiel,et al. Risk of angioedema following invasive or surgical procedures in HAE type I and II – the natural history , 2013, Allergy.
[254] J Dempster,et al. In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency , 2013, Clinical and experimental immunology.
[255] M. Magerl,et al. Practical Approach to Self-Administration of Intravenous C1-INH Concentrate: A Nursing Perspective , 2013, International Archives of Allergy and Immunology.
[256] W. Lumry,et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. , 2013, The Journal of pediatrics.
[257] T. Craig,et al. Review of Recent Guidelines and Consensus Statements on Hereditary Angioedema Therapy with Focus on Self-Administration , 2013, International Archives of Allergy and Immunology.
[258] A. Gompel,et al. Benefits of progestin contraception in non‐allergic angioedema , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[259] H. Farkas,et al. Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. , 2013, The Journal of allergy and clinical immunology.
[260] T. Craig,et al. Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. , 2013, Allergy and asthma proceedings.
[261] A. Sheffer,et al. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[262] W. Aberer,et al. Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment , 2013, PloS one.
[263] T. Klingebiel,et al. Does Early Clinical Manifestation of Hereditary Angioedema (HAE) Influence the Clinical Course of the Disease , 2013 .
[264] H. Farkas,et al. Prophylactic therapy in children with hereditary angioedema. , 2013, The Journal of allergy and clinical immunology.
[265] M. Cicardi,et al. Diagnosing angioedema. , 2013, Immunology and allergy clinics of North America.
[266] T. Caballero. Angio-oedema due to hereditary C1 inhibitor deficiency in children. , 2013, Allergologia et immunopathologia.
[267] M. Pedrosa,et al. Management of dental-oral procedures in patients with hereditary angioedema due to C1 inhibitor deficiency. , 2013, Journal of investigational allergology & clinical immunology.
[268] M. Mannesse,et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. , 2012, Journal of biotechnology.
[269] H. Farkas,et al. Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema and a history of four miscarriages. , 2012, European journal of obstetrics, gynecology, and reproductive biology.
[270] W. Aberer,et al. International consensus on hereditary and acquired angioedema. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[271] H. Farkas,et al. Short‐term prophylaxis in hereditary angioedema due to deficiency of the C1‐inhibitor – a long‐term survey , 2012, Allergy.
[272] R. Lockey,et al. WAO Guideline for the Management of Hereditary Angioedema , 2012, The World Allergy Organization journal.
[273] Adrian F Hernandez,et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. , 2012, Archives of internal medicine.
[274] T. Nowak,et al. Pathogen safety of human C1 esterase inhibitor concentrate , 2012, Transfusion.
[275] P. Martus,et al. Development and construct validation of the angioedema quality of life questionnaire , 2012, Allergy.
[276] T. Machnig,et al. Per-Attack Reporting of Prodromal Symptoms Concurrent with C1-Inhibitor Treatment of Hereditary Angioedema Attacks , 2012, Advances in Therapy.
[277] A. Knulst,et al. Clinical impact of peripheral attacks in hereditary angioedema patients. , 2012, The American journal of medicine.
[278] B. Zuraw,et al. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. , 2012, The American journal of medicine.
[279] K. Bork,et al. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. , 2012, The Journal of allergy and clinical immunology.
[280] E. Remor,et al. Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project , 2012, Health and Quality of Life Outcomes.
[281] M. Frank. Hereditary angioedema: short-term prophylaxis for surgery. , 2012, Allergy and asthma proceedings.
[282] M. Abuzakouk,et al. Danazol-Induced Hepatocellular Carcinoma in a Patient with Hereditary Angioedema , 2012, Journal of Gastrointestinal Cancer.
[283] M. Triggiani,et al. Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension study , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[284] D. Meyer‐Olson,et al. Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies , 2012, European Journal of Pediatrics.
[285] A. Huitema,et al. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. , 2012, Clinical immunology.
[286] Tom Bowen,et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. , 2012, The Journal of allergy and clinical immunology.
[287] M. Triggiani,et al. Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group , 2012, Allergy.
[288] T. Klingebiel,et al. Home therapy with intravenous human C1‐inhibitor in children and adolescents with hereditary angioedema , 2012, Transfusion.
[289] J. Cronin,et al. Treatment of an acute attack of type III hereditary angioedema with ecallantide. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[290] T. Machnig,et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study , 2011, Allergy.
[291] C. Town,et al. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[292] J. Koziol,et al. Safety and Efficacy of Physician-Supervised Self-Managed C1 Inhibitor Replacement Therapy , 2011, International Archives of Allergy and Immunology.
[293] B. Zuraw,et al. Pathophysiology of Hereditary Angioedema , 2011, American journal of rhinology & allergy.
[294] P. Howarth,et al. New topics in bradykinin research , 2011, Allergy.
[295] M. López-Trascasa,et al. SERPING1 mutations in 59 families with hereditary angioedema. , 2011, Molecular immunology.
[296] D. Solé,et al. Brazilian guidelines for the diagnosis and treatment of hereditary angioedema , 2011, Clinics.
[297] T. Craig,et al. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials. , 2011, Allergy and asthma proceedings.
[298] A. Sheffer,et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. , 2011, The Journal of allergy and clinical immunology.
[299] K. Bork,et al. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. , 2011, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[300] P. Bossuyt,et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations , 2011, Allergy.
[301] Gordon H Guyatt,et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.
[302] H. Farkas,et al. Long‐term efficacy of danazol treatment in hereditary angioedema , 2011, European journal of clinical investigation.
[303] M. Cicardi,et al. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21‐month prospective study in a cohort of 103 patients , 2011, Allergy.
[304] M. Maurer,et al. Long‐term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[305] M. López-Trascasa,et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. , 2011, Journal of investigational allergology & clinical immunology.
[306] M. López-Trascasa,et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. , 2011, Journal of investigational allergology & clinical immunology.
[307] M. Zilberberg,et al. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. , 2010, Allergy and asthma proceedings.
[308] J. Bernstein,et al. Successful C1 inhibitor short-term prophylaxis during redo mitral valve replacement in a patient with hereditary angioedema , 2010, Journal of cardiothoracic surgery.
[309] J. Nuijens,et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.
[310] H. Farkas,et al. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. , 2010, European journal of obstetrics, gynecology, and reproductive biology.
[311] J. Bernstein,et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. , 2010, The New England journal of medicine.
[312] A. Sheffer,et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. , 2010, The New England journal of medicine.
[313] William H. Yang,et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.
[314] J. Bernstein,et al. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[315] T. Klingebiel,et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. , 2010, American journal of obstetrics and gynecology.
[316] T. Bowen. Hereditary Angioedema Consensus 2010 , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.
[317] T. Klingebiel,et al. On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.
[318] P. Keith,et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.
[319] H. Farkas. Pediatric hereditary angioedema due to C1-inhibitor deficiency. , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.
[320] M. Gompels,et al. HAE international home therapy consensus document , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.
[321] William H. Yang,et al. Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary Angioedema , 2010, Journal of Clinical Immunology.
[322] W. Lumry,et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[323] A. Neskovic,et al. Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis. , 2010, Clinical therapeutics.
[324] K. Bork,et al. Economic costs associated with acute attacks and long-term management of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[325] T. Klingebiel,et al. Pharmacokinetic analysis of human plasma–derived pasteurized C1‐inhibitor concentrate in adults and children with hereditary angioedema: a prospective study , 2010, Transfusion.
[326] H. Farkas,et al. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema—a longitudinal study , 2010, European Journal of Clinical Pharmacology.
[327] A. Bygum,et al. Hereditary angio‐oedema in Denmark: a nationwide survey , 2009, The British journal of dermatology.
[328] J. Cesbron,et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[329] J. Bernstein,et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.
[330] T. Klingebiel,et al. C1‐inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis , 2009, Transfusion.
[331] B. Zuraw,et al. Pathogenesis and laboratory diagnosis of hereditary angioedema. , 2009, Allergy and asthma proceedings.
[332] K. Bork,et al. Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. , 2009, The American journal of medicine.
[333] G. Guyatt,et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines , 2009, Allergy.
[334] H. Farkas,et al. Disease expression in women with hereditary angioedema. , 2008, American journal of obstetrics and gynecology.
[335] H. Joller-jemelka,et al. Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. , 2008, Journal of immunological methods.
[336] A. Tordai,et al. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. , 2008, Molecular immunology.
[337] T. Craig. Appraisal of danazol prophylaxis for hereditary angioedema. , 2008, Allergy and asthma proceedings.
[338] P. Gorman. Hereditary angioedema and pregnancy: a successful outcome using C1 esterase inhibitor concentrate. , 2008, Canadian family physician Medecin de famille canadien.
[339] K. Bork,et al. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[340] William H. Yang,et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[341] H. Farkas,et al. Management of Hereditary Angioedema in Pediatric Patients , 2007, Pediatrics.
[342] Yung-Yee Chang,et al. Intracranial hypertension associated with danazol withdrawal: a case report. , 2007, Acta neurologica Taiwanica.
[343] M. Tarzi,et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio‐oedema , 2007, Clinical and experimental immunology.
[344] H. Farkas,et al. Helicobacter pylori Infection as a Triggering Factor of Attacks in Patients with Hereditary Angioedema , 2007 .
[345] H. Schuitemaker,et al. Viral safety of C1-inhibitor NF. , 2007, Biologicals : journal of the International Association of Biological Standardization.
[346] P. Schlattmann,et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). , 2007, The Journal of allergy and clinical immunology.
[347] M. Gulec,et al. A successful pregnancy and uncomplicated labor with C1INH concentrate prophylaxis in a patient with hereditary angioedema. , 2007, Allergologia et immunopathologia.
[348] K. Bork. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. , 2006, Immunology and allergy clinics of North America.
[349] C. Weiler,et al. Genetic test indications and interpretations in patients with hereditary angioedema. , 2006, Mayo Clinic proceedings.
[350] D. Churchill,et al. Pregnancy and C1 esterase inhibitor deficiency: a successful outcome , 2006, Archives of Gynecology and Obstetrics.
[351] K. Bork,et al. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. , 2006, Biochemical and biophysical research communications.
[352] K. Bork,et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.
[353] A. Eckardt,et al. Symptoms, Course, and Complications of Abdominal Attacks in Hereditary Angioedema Due to C1 Inhibitor Deficiency , 2006, The American Journal of Gastroenterology.
[354] A. Eerenberg,et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.
[355] A. Kaplan,et al. Continuing Medical EducationAngioedema , 2005 .
[356] M. Tang,et al. Hereditary angio‐oedema in children: A management guideline , 2005, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[357] H. Longhurst. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? , 2005, International journal of clinical practice.
[358] M. Gompels,et al. C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.
[359] K. Kragballe,et al. Hereditary Angioedema. , 2018, The New England journal of medicine.
[360] William H. Yang,et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2004, The Journal of allergy and clinical immunology.
[361] H. Griffiths,et al. Normal complement C4 values do not exclude hereditary angioedema , 2004, Journal of Clinical Pathology.
[362] R. Couture,et al. Capillary permeability induced by intravenous neurokinins , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.
[363] J. Stewart,et al. Analysis of the receptors mediating vascular actions of bradykinin , 1987, Naunyn-Schmiedeberg's Archives of Pharmacology.
[364] E. Whalley,et al. Analysis of the mechanism of action of bradykinin on human basilar artery in vitro , 1987, Naunyn-Schmiedeberg's Archives of Pharmacology.
[365] J. Lindner,et al. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert® P) in hereditary angioedema: a review , 2003 .
[366] B. Zuraw. Diagnosis and management of hereditary angioedema: an American approach. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[367] K. Bork,et al. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. , 2003, Journal of the American Dental Association.
[368] G. Chrousos,et al. Endocrine withdrawal syndromes. , 2003, Endocrine reviews.
[369] K. Bork,et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. , 2003, Archives of internal medicine.
[370] J. Lindner,et al. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. jean.de.serres@aventis.com. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[371] M. Cicardi,et al. Bradykinin-mediated angioedema. , 2002, The New England journal of medicine.
[372] H. Farkas,et al. Clinical management of hereditary angio‐oedema in children , 2002, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[373] K. Bork,et al. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. , 2002, Journal of hepatology.
[374] M. Silverberg,et al. Pathways for bradykinin formation and inflammatory disease. , 2002, The Journal of allergy and clinical immunology.
[375] K. Bork,et al. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. , 2001, Archives of internal medicine.
[376] S. Choquet,et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. , 2000, The Journal of allergy and clinical immunology.
[377] K. Binkley,et al. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. , 2000, The Journal of allergy and clinical immunology.
[378] K. Bork,et al. Hereditary angioedema with normal C1-inhibitor activity in women , 2000, The Lancet.
[379] K. Bork,et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. , 2000, Mayo Clinic proceedings.
[380] N. Black,et al. Consensus Development Methods: A Review of Best Practice in Creating Clinical Guidelines , 1999, Journal of health services research & policy.
[381] H. Farkas,et al. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. , 1999, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[382] K. Bork,et al. Hepatocellular adenomas in patients taking danazol for here ditary angiooedema , 1999, The Lancet.
[383] M. Cicardi,et al. Plasma bradykinin in angio-oedema , 1998, The Lancet.
[384] F. Rosen,et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema , 1998, Transfusion.
[385] A. Black,et al. Angiotensin–converting enzyme (ACE) inhibitors and angio–oedema , 1997, The British journal of dermatology.
[386] H. Galan,et al. Fresh frozen plasma prophylaxis for hereditary angioedema during pregnancy. A case report. , 1996, The Journal of reproductive medicine.
[387] F. Rosen,et al. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. , 1996, The New England journal of medicine.
[388] T. Mollnes,et al. C1 Inhibitor and Diagnosis of Hereditary Angioedema in Newborns , 1994, Pediatric Research.
[389] P. Brunskill. The effects of fetal exposure to danazol , 1992, British journal of obstetrics and gynaecology.
[390] T. Hedner,et al. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. , 1992, BMJ.
[391] P. Brunskill. The effects of fetal exposure to danazol , 1992 .
[392] S. Leodolter,et al. C1-Esterase Inhibitor in Uncomplicated Pregnancy and Mild and Moderate Preeclampsia , 1991, Thrombosis and Haemostasis.
[393] Wellbutrin,et al. Prescribing Information , 2015, European journal of haematology.
[394] B. Wüthrich,et al. Angioedema. A review on the acquired, allergic or non-allergic, and the hereditary forms. , 1990, Recenti progressi in medicina.
[395] A. Kaplan,et al. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. , 1983, The Journal of allergy and clinical immunology.
[396] F. Rosen,et al. Kinin generation in hereditary angioneurotic edema (H.A.N.E.) plasma. , 1983, Advances in experimental medicine and biology.
[397] M. Cicardi,et al. Hereditary Angioedema: An Appraisal of 104 Cases , 1982, The American journal of the medical sciences.
[398] A. C. Wentz. Adverse effects of danazol in pregnancy. , 1982, Annals of internal medicine.
[399] A. Sheffer,et al. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. , 1981, The Journal of allergy and clinical immunology.
[400] D. Ogston,et al. C1 inactivator level in pregnancy. , 1981, Thrombosis research.
[401] M. Cicardi,et al. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. , 1980, The Journal of allergy and clinical immunology.
[402] A. Sheffer,et al. Methyltestosterone therapy in hereditary angioedema. , 1977, Annals of internal medicine.
[403] Black Wp. Danazol in the treatment of hereditary angio-neurotic oedema. , 1977 .
[404] W. P. Blackmore. Danazol in the treatment of hereditary angio-neurotic oedema. , 1977, The Journal of international medical research.
[405] D. Alling,et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.
[406] B. Zweiman,et al. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. , 1976, Blood.
[407] D. Alling,et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.
[408] F. Kueppers,et al. Half‐life of CINH in hereditary angioneurotic oedema (HAE) * , 1975, Clinical allergy.
[409] C. Gwynn. Therapy in hereditary angioneurotic oedema , 1974, Archives of disease in childhood.
[410] Schulz Kh. [Hereditary Quincke's edema. New therapeutic ways]. , 1974 .
[411] K. Schulz. [Hereditary Quincke's edema. New therapeutic ways]. , 1974, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[412] B. Lundh. Tranexamic acid in hereditary angioneurotic edema--a progress report. , 1973, The New England journal of medicine.
[413] V. Donaldson. Kinin formation in hereditary angioneurotic edema (HANE) plasma. , 1973, International archives of allergy and applied immunology.
[414] G. Blohmé. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. , 2009 .
[415] P. Schur,et al. Acquired C1 inhibitor deficiency in lymphosarcoma , 1972 .
[416] A. Sheffer,et al. Tranexamic acid therapy in hereditary angioneurotic edema. , 1972, The New England journal of medicine.
[417] Norman Crolee Dalkey,et al. An experimental study of group opinion , 1969 .
[418] F. Rosen,et al. The "neurotic edema" (hereditary angioedema). , 1969, The New England journal of medicine.
[419] T. White,et al. A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid. Studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism. , 1968, Clinical and experimental immunology.
[420] F. Rosen,et al. Hereditary Angioneurotic Edema: Two Genetic Variants , 1965, Science.
[421] Uno Eriksoni. Peripheral Arteriography during Bradykinin Induced Vasodilation , 1965 .
[422] F. Rosen,et al. ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE. , 1964, The Journal of clinical investigation.
[423] R. R. Evans,et al. A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. , 1963, The American journal of medicine.
[424] M. Rocha e Silva,et al. Coronary Vasodilation Produced by Bradykinin on Isolated Mammalian Heart , 1962, Circulation research.
[425] M. Rocha e Silva,et al. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. , 1949, The American journal of physiology.
[426] E. Dinkelacker. Ueber acutes Oedem , 1882 .